Based on target product profiles of Hovione’s business partners, we identified the need to develop a portfolio of inhalers to address requirements for a product that maximized simplicity of use and industrial manufacturability. As a result, Hovione’s inhalers exhibit the lowest number of parts and an absence of metal needles, springs or blades.
The present portfolio is structured to address two main areas of therapeutic intervention: acute treatment and chronic treatment.
For acute treatments, Hovione offers the TwinCaps, the world’s first market approved, single use, disposable inhaler. This cavity-based device allows the effective delivery of up to 50 mg of powder per cavity.
For chronic treatments, Hovione offers the PowdAir, a simple, reusable, capsule based (size 3 HPMC) metal-less inhaler.